Exhiva

Exciva is a private German clinical-stage biotech developing therapies for neuropsychiatric symptoms associated with dementia, with an initial focus on agitation in Alzheimer's disease dementia. The company's lead program is Deraphan, also referred to as EXV-802, a proprietary combination of dextromethorphan and a 5-HT2A/2C receptor inverse agonist. Exciva completed a Phase 1 study for EXV-802 in 2022, received FDA Fast Track designation in 2024, and in January 2026 raised a €51 million Series B to fund a Phase 2 study. The company is based in Heidelberg and positions itself around developing first-in-class and best-in-class treatments in neuropsychiatry.